"10.1371_journal.pone.0052129","plos one","2012-12-14T00:00:00Z","Brooke Levis; Andrea Burri; Marie Hudson; Murray Baron; Brett D Thombs; Canadian Scleroderma Research Group (CSRG)","Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada; Department of Twin Research and Genetic Epidemiology, Kings College, London, United Kingdom; Psychopathology and Clinical Intervention, Institute of Psychology, University of Zürich, Zürich, Switzerland; Department of Medicine, McGill University, Montréal, Québec, Canada; Department of Psychiatry, McGill University, Montréal, Québec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada; Department of Educational and Counselling Psychology, McGill University, Montréal, Québec, Canada; School of Nursing, McGill University, Montréal, Québec, Canada","¶ Membership of the Canadian Scleroderma Research Group is provided in the Acknowledgments.","The Canadian Scleroderma Research Group (CSRG) has received commercial funding from INOVA Diagnostics Inc, Dr. Fooke Laboratorien GmbH, Euroimmun, Mikrogen GmbH, Actelion Pharmaceuticals and Pfizer Inc. For the present study, the authors used data collected via the CSRG Registry. Apart from this, no commercial funding was used to conduct the present study, and the commercial funders of the CSRG have no knowledge that the present study was conducted. Nonetheless, for full transparency, the authors declare that INOVA Diagnostics Inc, Dr. Fooke Laboratorien GmbH, Euroimmun, Mikrogen GmbH, Actelion Pharmaceuticals and Pfizer Inc. have provided unrestricted educational and research funds to the Canadian Scleroderma Research Group. The commercial funding that provides support to the CSRG does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","12","Brooke Levis","BL",6,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
